IP Library › Granted Patent US 7,858,083
Granted Patent B2
US 7,858,083 · App. 12/327,936 · Granted Dec 28, 2010

Pan cancer oncolytic vectors and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,858,083
App. No.
12/327,936
Granted
Dec 28, 2010
Kind
B2
Abstract

Replication-competent adenoviral vectors which selectively replicate in cancer cells are provided. The replication-competent viral vectors comprise an E2F responsive promoter and/or a telomerase promoter operatively linked to an adenoviral coding region. The replication-competent adenoviral vectors effectively replicate in a variety of types of cancer cells and find broad utility in the treatment of cancer.

Claims (6)

1. A recombinant viral vector comprising an adenoviral nucleic acid sequence, wherein said nucleic acid sequence comprises in sequential order: a left inverted terminal repeat (ITR), an adenoviral packaging signal, an E2F responsive promoter operatively linked to an E1a coding sequence, a telomerase (TERT) promoter operatively linked to an E1b coding sequence and a right ITR, wherein said recombinant viral vector comprises SEQ ID NO:5.

2. A pharmaceutical composition comprising the adenoviral vector of claim 1 and a pharmaceutically acceptable carrier.

3. A method of selective cytolysis of a cancer cell, comprising contacting a cell population with an effective amount of an adenoviral vector comprising an adenoviral nucleic acid sequence presented as SEQ ID NO: 5, wherein said nucleic acid sequence comprises in sequential order: a left inverted terminal repeat (ITR), an adenoviral packaging signal, an E2F responsive promoter operatively linked to an E1a coding sequence, a telomerase (TERT) promoter operatively linked to an E1b coding sequence and a right ITR, under conditions where the adenoviral vector infects the cells of the cell population resulting in selectively cytolysis of cancer cells within said cell population.

4. The method of claim 3 , further comprising a mutation or deletion in an E3 coding sequence.

5. The method of claim 3 , wherein at least one E3 coding sequence has been deleted from the adenoviral nucleic acid sequence.

6. The method of claim 3 , wherein an E3 coding sequence in the nucleic acid sequence codes for at least one native E3 protein.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Nov 24, 2021
From: CITIZENS BANK, N.A., AS ADMINISTRATIVE AGENT
To: ANI PHARMACEUTICALS, INC.; ANIP ACQUISITION COMPANY
Reel/Frame 058207/0746 →
RELEASE OF SECURITY INTEREST Recorded Nov 24, 2021
From: CITIZENS BANK, N.A., AS ADMINISTRATIVE AGENT
To: ANIP ACQUISITION COMPANY; ANI PHARMACEUTICALS, INC.
Reel/Frame 058207/0891 →
CHANGE OF NAME Recorded Nov 9, 2020
From: COLD GENESYS, INC.
To: CG ONCOLOGY, INC.
Reel/Frame 054362/0411 →
SECURITY INTEREST Recorded Dec 27, 2018
From: ANI PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 047860/0931 →
SECURITY INTEREST Recorded Dec 29, 2017
From: ANI PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 044504/0575 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2010
From: BIOSANTE PHARMACEUTICALS, INC.
To: COLD GENESYS, INC.
Reel/Frame 025550/0722 →
MERGER Recorded Mar 22, 2010
From: CELL GENESYS, INC.
To: BIOSANTE PHARMACEUTICALS, INC.
Reel/Frame 024114/0688 →
AGREEMENT AND PLAN OF MERGER Recorded Feb 2, 2010
From: CELL GENESYS, INC.
To: BIOSANTE PHARMACEUTICALS, INC.
Reel/Frame 023882/0442 →